The drumbeat for the federal government to step in and negotiate the price of specialty drugs for patients gets louder and louder. Health and Human Services Secretary Sylvia Burwell told the Atlantic’s Washington Ideas Forum on Thursday that, “One of the most important tools that we could gain would be an ability to negotiate.”
Morning Consult reports that Burwell was responding to a question about outrage stirred by the price of the EpiPen. If Medicare and Medicaid could negotiate directly with pharmaceutical companies such as Mylan Pharmaceuticals (which manufactures the EpiPen), then the entire uproar may have been averted, Burwell said.
Source: Morning Consult